LifeMD, Inc. (NASDAQ:LFMD) Shares Acquired by Royce & Associates LP

Royce & Associates LP boosted its holdings in LifeMD, Inc. (NASDAQ:LFMD) by 23.9% during the fourth quarter, HoldingsChannel reports. The fund owned 1,115,991 shares of the company’s stock after buying an additional 214,950 shares during the period. Royce & Associates LP’s holdings in LifeMD were worth $5,524,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new position in shares of LifeMD in the 3rd quarter valued at $54,000. Magnus Financial Group LLC raised its holdings in LifeMD by 31.1% in the 4th quarter. Magnus Financial Group LLC now owns 16,000 shares of the company’s stock valued at $79,000 after buying an additional 3,792 shares during the period. MetLife Investment Management LLC lifted its position in LifeMD by 129.1% in the third quarter. MetLife Investment Management LLC now owns 21,138 shares of the company’s stock valued at $111,000 after buying an additional 11,910 shares during the last quarter. Integrated Investment Consultants LLC purchased a new position in LifeMD during the third quarter worth about $129,000. Finally, Centiva Capital LP acquired a new stake in shares of LifeMD during the third quarter valued at about $196,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CMO Jessica Friedeman sold 30,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $5.66, for a total transaction of $169,800.00. Following the transaction, the chief marketing officer now owns 170,000 shares of the company’s stock, valued at $962,200. This trade represents a 15.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the sale, the chief executive officer now directly owns 2,703,715 shares of the company’s stock, valued at approximately $14,032,280.85. This represents a 0.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,000 shares of company stock valued at $677,050 in the last ninety days. 15.97% of the stock is currently owned by company insiders.

LifeMD Stock Performance

Shares of LFMD stock opened at $5.72 on Thursday. LifeMD, Inc. has a 1 year low of $3.99 and a 1 year high of $12.88. The firm has a market cap of $255.02 million, a price-to-earnings ratio of -8.94 and a beta of 1.50. The stock’s 50-day moving average is $5.70 and its two-hundred day moving average is $5.40.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $64.26 million for the quarter, compared to analyst estimates of $57.43 million. As a group, research analysts predict that LifeMD, Inc. will post -0.56 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on LFMD shares. KeyCorp decreased their price target on LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Mizuho started coverage on LifeMD in a research note on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price on the stock. HC Wainwright lifted their target price on LifeMD from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, March 12th. Lake Street Capital started coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target on the stock. Finally, B. Riley upgraded shares of LifeMD to a “strong-buy” rating in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $11.43.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.